ClinicalTrials.gg
RecruitingNCT07065760Updated May 15, 2026

University of Utah PS-IDE: Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms

An interventional study of Endovascular Aneurysm Repair with Physician Modified Endograft in Juxtarenal Abdominal Aortic Aneurysm, sponsored by Cali Johnson. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Cali Johnson · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 122 studies in Aortic Aneurysm, Abdominal with a site in United States — 28 open to participants now, 34 under way, 1 of them phase 3. Aortic Aneurysm, Abdominal · United States.

Planned enrollment
73rd of 85
15 · median 94
Started
2025
with 3 others
No phase
64 of 122
14 open now
Primary completion
2027-08
later than 15 of 33 live
Registered
118th of 122
by date

Among the 122 studies in Aortic Aneurysm, Abdominal with a site in United States, this one is the 73rd largest by planned enrollment of the 85 interventional ones that give a count, is one of 4 that started in 2025, is one of 64 with no phase, reaches primary completion later than 15 of the 33 other live ones, and was the 118th registered.

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

Browse Aortic Aneurysm, Abdominal studies →

Open to participants now

28 of the 122 studies in Aortic Aneurysm, Abdominal with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Aortic Aneurysm, Abdominal with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effects of a physician-modified endovascular graft (PMEG) for juxtarenal aortic aneurysms by collecting data on its performance. Participants in the study will undergo surgery to repair their juxtarenal aortic aneurysm using the PMEG device. After the surgery, participants will attend several follow-up visits to monitor their recovery and the device's effectiveness. These follow-up visits will take place at hospital discharge, then at 1 month, 6 months, 12 months, and once a year for up to 5 years after surgery.

Read the detailed description

A juxtarenal aortic aneurysm is an aneurysm that occurs near the renal arteries, which bring blood to the kidneys. This research study will evaluate if the physician-modified endovascular graft (PMEG) is safe and effective in the treatment of juxtarenal aortic aneurysms. The PMEG device is an investigational device, which means it has not been approved by the FDA. The device is designed to create a pathway through the aneurysm for blood flow to the arteries, reducing the blood pressure that the aneurysm experiences. There are several types of endovascular devices depending on how big the aneurysm is, where the aneurysm is located in relation to the kidney, or other physical measurements of the blood vessels. The upper portion of the device, or stent graft, will include between one and four holes (fenestrations). The holes allow the device to be located above the renal arteries (the blood vessels that supply blood to the kidneys) without blocking the blood flow to them. Smaller grafts are then placed in the blood vessels to the kidneys, the intestines, and liver to be connected to the main aortic graft, allowing blood to flow to the organs.

03

Conditions studied

  • Juxtarenal Abdominal Aortic Aneurysm

Keywords

  • physician modified endovascular graft
  • juxtarenal abdominal aortic aneurysm
  • PMEG
  • FEVAR
  • Endovascular Aortic Repair
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is ≥ 18 years of age
  2. Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study)
  3. Patient or Legally Authorized Representative has signed an Institutional Review Board (IRB) approved Form
  4. Patient has a juxtarenal abdominal aortic aneurysm that meets at least one of the following:

    1. An aneurysm with a maximum diameter of ≥ 5.5 cm for male (≥ 5.0 cm for female) or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e., perpendicular to the centerline) measurements
    2. Aneurysm with a history of growth > 0.5 cm in 6 months
    3. Saccular aneurysm deemed at significant risk for rupture
    4. Symptomatic aneurysm
    5. Ruptured aneurysm
  5. Patient has patent iliac or femoral arteries, with or without the use of conduit, that will allow endovascular access with the physician modified endovascular graft.
  6. Patient has a suitable non-aneurysmal proximal aortic neck of ≥ 2 mm inferior to the most distal renal artery ostium.
  7. Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of ≥ 15mm. The resultant repair should preserve patency in at least one hypogastric artery.
  8. Patient has a suitable non-aneurysmal proximal aortic neck diameter between 20 and 32 mm, averaged across the diameters at the Celiac, SMA, at the lowest patent renal artery and at the midpoint of the renal arteries.
  9. Patient has suitable non-aneurysmal distal common iliac diameters between 8 and 20 mm.
  10. Patient has juxtarenal aortic neck angulation ≤ 60°
  11. Target branch vessel diameter ≥ 5 mm.
  12. Patient must be willing to comply with all required follow-up exams.

Exclusion criteria

Exclusion Criteria:

  1. Patient has a mycotic aneurysm or has an active systemic or local infection that may increase the risk of endovascular infection
  2. Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina)
  3. Patient has a major surgical or interventional procedure, not related to the endovascular repair, planned within +/- 30 days of the AAA repair.
  4. Patient has history of an aortopathic connective tissue disease (e.g. Marfan's or Ehler's-Danlos syndrome).
  5. Patient has a known or to anticoagulation or contrast media that is not amenable to pre-treatment.
  6. Patient has known allergy or intolerance to stainless steel, nitinol or gold (gold-coated tungsten).
  7. Patient has a body habitus that would inhibit X-ray visualization of the aorta
  8. Patient has a limited of less than 1 year
  9. Patient is currently participating in another device or drug clinical trial
  10. Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.
  11. Thrombus or excessive calcification within the neck of the aneurysm
  12. Branch vessel stenosis ≥ 80%
  13. Patient treatable on label with FDA approved EVAR or FEVAR device and can wait for device availability.
  14. Subject is willing and eligible to enroll in a manufacturer-sponsored study at the investigational site, or the subject is willing and eligible to participate in a study with a manufacturer-made device at another institution.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Physician Modified Endograft

    Surgical procedure to repair the juxtarenal abdominal aortic aneurysm, during which the physician-modified endovascular graft (PMEG) device will be used.

    Device: Endovascular Aneurysm Repair with Physician Modified Endograft

Interventions

  • DeviceEndovascular Aneurysm Repair with Physician Modified Endograft

    The surgeon will make an incision to access the femoral artery and insert a thin wire to guide the catheter to the juxtarenal aortic aneurysm. The main graft will be modified by hand to match the participant's anatomy, then reloaded and guided through the artery to the aorta. Once in place, the graft will be deployed, and additional stents will be inserted into vital arteries that supply the kidneys and bowels. Two smaller grafts will be placed into the iliac arteries.This allows blood to flow to the target organs and legs, protecting the aneurysm from rupture. All catheters will then be removed, leaving the graft in place, and the incisions will be closed.

06

What researchers measure

Primary outcomes

  1. All Cause Mortality

    The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including all-cause mortality.

    Time frame: 30 days post index procedure

  2. Myocardial Infarction

    The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including myocardial infarction.

    Time frame: 30 days post index procedure

  3. Stroke

    The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including stroke.

    Time frame: 30 days post index procedure

  4. Renal Failure

    The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including renal failure.

    Time frame: 30 days post index procedure

  5. Respiratory Failure

    The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including respiratory failure.

    Time frame: 30 days post index procedure

  6. Paraplegia

    The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including paraplegia.

    Time frame: 30 days post index procedure

  7. Bowel Ischemia

    The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including bowel ischemia.

    Time frame: 30 days post procedure

  8. Procedural Blood Loss (>1000 cc)

    The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including procedural blood loss (\>1000 cc).

    Time frame: 30 days post procedure

  9. Treatment Success

    The primary effectiveness endpoint is the proportion of subjects that achieve Treatment Success. Treatment Success is a composite endpoint assessed at 12 months that requires the following criteria to be met: Technical Success (at the index procedure) is defined by the following: 1. The physician was able to insert the delivery catheter and deliver the physician modified endovascular graft to the treatment site and preserve blood flow into the vessels intended to have blood flow preserved. 2. Freedom from Type I \& III endoleaks at 12 months 3. Freedom from stent graft migration at 12 months 4. Freedom from aortic aneurysm enlargement at 12 months 5. Freedom from aortic aneurysm rupture and conversion to open repair through 12 months

    Time frame: 12 months post index procedure

Secondary outcomes

  1. Mortality

    Secondary safety endpoints will be evaluated at 30 days, 6 months, \& 12 months following the initial implant procedure and annually through 5 years, including mortality.

    Time frame: 30 days, 6 months, and annually through 5 years post index procedure

  2. Aneurysm related mortality

    Secondary safety endpoints will be evaluated at 30 days, 6 months, \& 12 months following the initial implant procedure and annually through 5 years, including aneurysm related mortality.

    Time frame: 30 days, 6 months, and annually through 5 years post index procedure

  3. Aneurysm Rupture

    Secondary safety endpoints will be evaluated at 30 days, 6 months, \& 12 months following the initial implant procedure and annually through 5 years, including aneurysm rupture.

    Time frame: 30 days, 6 months, and annually through 5 years post index procedure.

  4. Major Adverse Events (MAE)

    Secondary safety endpoints will be evaluated at 30 days, 6 months, \& 12 months following the initial implant procedure and annually through 5 years, including major adverse events.

    Time frame: 30 days, 6 months, and annually through 5 years post index procedure

  5. Renal failure with or without permanent dialysis

    Secondary safety endpoints will be evaluated at 30 days, 6 months, \& 12 months following the initial implant procedure and annually through 5 years, including renal failure with or without permanent dialysis.

    Time frame: 30 days, 6 months, and annually through 5 years post index procedure.

  6. Graft Infection

    Secondary safety endpoints will be evaluated at 30 days, 6 months, \& 12 months following the initial implant procedure and annually through 5 years, including graft infection.

    Time frame: 30 days, 6 months, and annually through 5 years post index procedure.

  7. Technical Success

    Secondary effectiveness endpoints will be evaluated including technical success. Technical Success (evaluated at 30-days) is a composite of the following: a. Successful access to the arterial system using remote arterial exposure, percutaneous technique, or open surgical conduits; b. Successful delivery and deployment at the intended implantation site; c. Successful side branch catheterization and placement of bridging stents with restoration and maintenance of flow in all intended target vessels; d. Successful withdrawal of the delivery system; e. Patency of all endovascular graft and stent components; f. Absence of device deformations requiring unplanned placement of an additional device; g. Absence of Type I and III endoleaks at completion angiography that extends beyond 30 days by confirmatory imaging

    Time frame: 30 days, 6 months, and annually through 5 years post index procedure

  8. Stent graft migration > 10 mm

    Secondary effectiveness endpoints will be evaluated including stent graft migration \> 10 mm.

    Time frame: 30 days, 6 months, and annually through 5 years post index procedure.

  9. All endoleaks

    Secondary effectiveness endpoints will be evaluated including all endoleaks.

    Time frame: 30 days, 6 months, and annually through 5 years post index procedure.

  10. AAA enlargement

    Secondary effectiveness endpoints will be evaluated including AAA enlargement.

    Time frame: 30 days, 6 months, and annually through 5 years post index procedure.

  11. Patency related events

    Secondary effectiveness endpoints will be evaluated including patency related events.

    Time frame: 30 days, 6 months, and annually through 5 years post index procedure.

  12. Device integrity failure

    Secondary effectiveness endpoints will be assessed including device integrity failure.

    Time frame: 30 days, 6 months, and annually through 5 years post index procedure.

  13. Conversion to open repair

    Secondary effectiveness endpoints will be evaluated including conversion to open repair.

    Time frame: 30 days, 6 months, and annually through 5 years post index procedure.

  14. Secondary Intervention

    Secondary effectiveness endpoints will be evaluated including secondary interventions.

    Time frame: 30 days, 6 months, and annually through 5 years post index procedure.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Aug 2027, 26 months after the start.

Of 51 non-industry interventional studies with no phase under Aortic Aneurysm, Abdominal, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 61. This study's planned 26 months is below that.

Counting every sponsor, half of 94 studies reached it within 43 months; a quarter within 23 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Jul 15, 2025
StartActual
May 15, 2025
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2032
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07065760
Lead sponsor
Cali Johnson
Responsible party
Cali Johnson (Assistant Professor, University of Utah) — Sponsor-investigator
First posted
Jul 15, 2025
Start date
May 15, 2025
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2032 (estimated)
Last update
May 15, 2026

Study contacts

Julie Hales, MSN, RN, CCRC
Contact
Julie.Hales@hsc.utah.edu
801-587-1450
Cali Johnson, MD, EdD
Contact
cali.johnson@hsc.utah.edu
801-213-6585
Cali Johnson, MD, EdD
principal investigator · University of Utah
Nathan Droz, MD
principal investigator · University of Utah

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion